Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Recruiting Study icon

Recruiting

Trial ID CA209-8TT  |   NCT03899155

Pan Tumor Rollover Study

Summary

  • Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • 160
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Signed Written Informed Consent.
    1. Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
      1. On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
        1. WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

          Exclusion Criteria

          Exclusion Criteria Icon
          :
          • Participant is not eligible for study treatment per the Parent Study eligibility criteria.
            1. Participants not receiving clinical benefit as assessed by the Investigator.
              1. Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
                1. Other protocol-defined Inclusion/Exclusion Criteria apply
                  Additional Information *

                  Treatment Options

                  Study Arms

                  ASSIGNED INTERVENTION

                  Study Arms

                  Experimental: A1: Nivolumab Monotherapy Dose 1

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab

                  Study Arms

                  Experimental: A2: Nivolumab Monotherapy Dose 2

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab

                  Study Arms

                  Experimental: B1: Nivolumab + Ipilimumab

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab, Ipilimumab

                  Study Arms

                  Experimental: B2: Nivolumab + Ipilimumab + Cabozantinib

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab, Ipilimumab, Cabozantinib

                  Study Arms

                  Experimental: B3: Nivolumab + Ipilimumab + Trametinib

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab, Ipilimumab, Trametinib

                  Study Arms

                  Experimental: C10: Relatlimab + Nivolumab SAV Dose 4

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C11: Relatlimab + Nivolumab SAV + PDCT Dose 2

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C12: Relatlimab + Nivolumab SAV Dose 5

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab + Relatlimab

                  Study Arms

                  Experimental: C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab + Relatlimab

                  Study Arms

                  Experimental: C4: Relatlimab + Nivolumab SAV Dose 2

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C5: Relatlimab + Nivolumab + Ipilimumab

                  ASSIGNED INTERVENTION
                  • Drug: Ipilimumab, Nivolumab

                  Study Arms

                  Experimental: C6: Relatlimab + Nivolumab + Capecitabine

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab + Relatlimab, Capecitabine

                  Study Arms

                  Experimental: C7: Relatlimab + Nivolumab SAV Dose 3

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C8: Relatlimab + Nivolumab SAV + PDCT Dose 1

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Nivolumab

                  Study Arms

                  Experimental: C9: Relatlimab + Nivolumab SAV + Bevacizumab

                  ASSIGNED INTERVENTION
                  • Drug: Relatlimab, Bevacizumab, Nivolumab

                  Study Arms

                  Experimental: D1: Nivolumab + Temozolomide

                  ASSIGNED INTERVENTION
                  • Drug: Temozolomide, Nivolumab

                  Study Arms

                  Experimental: D2: Nivolumab + Rucaparib

                  ASSIGNED INTERVENTION
                  • Drug: Rucaparib, Nivolumab

                  Study Arms

                  Experimental: D3: Nivolumab + Daratumumab

                  ASSIGNED INTERVENTION
                  • Drug: Daratumumab, Nivolumab

                  Study Arms

                  Experimental: D4: Nivolumab + Bevacizumab

                  ASSIGNED INTERVENTION
                  • Drug: Nivolumab

                  Study Arms

                  Experimental: E10: Pemetrexed Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Pemetrexed

                  Study Arms

                  Experimental: E11: Pembrolizumab Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Pembrolizumab

                  Study Arms

                  Experimental: E1: Bevacizumab Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Bevacizumab

                  Study Arms

                  Experimental: E2: Regorafinib Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Regorafinib

                  Study Arms

                  Experimental: E3: Leucovorin + Fluorouracil

                  ASSIGNED INTERVENTION
                  • Drug: Leucovorin

                  Study Arms

                  Experimental: E4: Leucovorin + Oxaliplatin + Fluorouracil

                  ASSIGNED INTERVENTION
                  • Drug: Leucovorin, Fluorouracil, Oxaliplatin

                  Study Arms

                  Experimental: E5: Enzalutamide Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Enzalutamide

                  Study Arms

                  Experimental: E6: Sunitinib Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Sunitinib

                  Study Arms

                  Experimental: E7: Rucaparib Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Rucaparib

                  Study Arms

                  Experimental: E8: Capecitabine Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Capecitabine

                  Study Arms

                  Experimental: E9: Cabozantinib Monotherapy

                  ASSIGNED INTERVENTION
                  • Drug: Cabozantinib
                  Please select a study site to register
                  Select a Study Site Location
                  Select a study site location that is convenient for you
                  Register
                  Provide your contact details for the study site to connect with you.

                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you